Literature DB >> 10328257

Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects.

B Pascual-Sedano1, A Iranzo, J Marti-Fàbregas, P Domingo, A Escartin, M Fuster, J L Barrio, M A Sambeat.   

Abstract

OBJECTIVE: To determine the frequency and etiologic and clinical aspects of new-onset seizures in patients with human immunodeficiency virus (HIV) infection.
DESIGN: A prospective survey of an HIV-infected patient cohort.
SETTING: Outpatients and inpatients in a university hospital in Barcelona, Spain. PATIENTS: Five hundred fifty HIV-infected patients recruited over 1 year. MAIN OUTCOME MEASURE: Analysis of new-onset seizures, with detailed medical history and appropriate workup.
RESULTS: Seventeen HIV-infected patients (3%) had a new-onset seizure during the study period. Fourteen (82%) of 17 patients had acquired immunodeficiency syndrome diagnosed according to the 1993 CDC Expanded AIDS Definition. Mean latency (+/-SD) between diagnosis of HIV infection and the first seizure was 60.7+/-37.6 months. Seizure cause was drug toxicity in 8 patients (47%) and intracranial lesion in 6 patients (35.3%). Two patients had seizures related to metabolic derangements. No cause was found in 1 case. The first seizure was generalized in 12 patients (70.6%), simple partial motor seizure in 2 (11.8%), and simple partial seizure evolving to generalized seizure in 3 (17.6%). We found partial seizures in 66.6% of patients who had intracranial lesions. Most patients were treated with phenytoin, which was well tolerated and effective in controlling seizures.
CONCLUSIONS: New-onset seizures are infrequent in patients with HIV. In most cases a definite or probable cause is identified, which is usually related to toxic and/or metabolic factors. Most seizures are generalized, and partial seizures suggest a focal cerebral lesion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328257     DOI: 10.1001/archneur.56.5.609

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

Review 1.  Seizures in HIV-seropositive individuals: epidemiology and treatment.

Authors:  Frank Romanelli; Melody Ryan
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

3.  An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.

Authors:  Yulin Zhang; Luxin Qiao; Wei Ding; Feili Wei; Qingxia Zhao; Xicheng Wang; Ying Shi; Ning Li; Davey Smith; Dexi Chen
Journal:  J Neurovirol       Date:  2012-03-13       Impact factor: 2.643

4.  Structural gray matter change early in male patients with HIV.

Authors:  Yunfang Li; Hongjun Li; Quansheng Gao; Da Yuan; Jing Zhao
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 5.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

7.  Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.

Authors:  Min Zhu; Sanjeev Kaul; Partha Nandy; Dennis M Grasela; Marc Pfister
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Human Immunodeficiency Viral Infection and Status Epilepticus in United States (2002-2009).

Authors:  Saqib A Chaudhry; Mohammad Rauf Afzal; Gustavo J Rodriguez; Shahram Majidi; Scott Bundlie; Ameer E Hassan; M Fareed K Suri; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2015-07

9.  Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

Authors:  Matthias Mehling; Henning Drechsler; Jens Kuhle; Martin Hardmeier; Ruediger Doerries; Stephan Ruegg; Achim Gass
Journal:  J Neurovirol       Date:  2008-01       Impact factor: 2.643

10.  Early antiretroviral therapy is protective against epilepsy in children with human immunodeficiency virus infection in botswana.

Authors:  David Bearden; Andrew P Steenhoff; Dennis J Dlugos; Dennis Kolson; Parth Mehta; Sudha Kessler; Elizabeth Lowenthal; Baphaleng Monokwane; Gabriel Anabwani; Gregory P Bisson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.